Day One Bio Files 8-K on Officer Changes, Reg FD Disclosure

TL;DR

**Day One Bio just filed an 8-K about officer changes and disclosures; check the full filing for details.**

AI Summary

Day One Biopharmaceuticals, Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024. This filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' as well as 'Regulation FD Disclosure' and 'Financial Statements and Exhibits.' While the specific details of these changes are not provided in this summary, investors should pay attention to the full filing to understand any new executive appointments or departures, and how these might impact the company's strategic direction and financial health, which could influence stock performance.

Why It Matters

Changes in executive leadership or compensation can signal shifts in company strategy or financial stability, directly impacting investor confidence and the stock's future trajectory.

Risk Assessment

Risk Level: medium — The filing indicates changes in officers and compensatory arrangements, which could be positive or negative depending on the specifics, introducing moderate uncertainty.

Analyst Insight

A smart investor would review the full 8-K filing to understand the specific details of the officer changes and compensatory arrangements, as these could significantly impact the company's future performance and valuation.

Key Players & Entities

• Day One Biopharmaceuticals, Inc. (company) — the registrant filing the 8-K
• January 16, 2024 (date) — date of the earliest event reported
• January 17, 2024 (date) — date the 8-K was filed
• 001-40431 (other) — Commission File Number

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share DAWN Nasdaq Global Select
• $588,000 — common stock with an aggregate value of $588,000, calculated in accordance with the Comp
• $294,000 — common stock with an aggregate value of $294,000 (the "Annual Grant"), calculated in acc

Filing Documents

• d722658d8k.htm (8-K) — 30KB
• d722658dex991.htm (EX-99.1) — 10KB
• g722658g93x03.jpg (GRAPHIC) — 4KB
• 0001193125-24-008941.txt ( ) — 172KB
• dawn-20240116.xsd (EX-101.SCH) — 3KB
• dawn-20240116_lab.xml (EX-101.LAB) — 18KB
• dawn-20240116_pre.xml (EX-101.PRE) — 11KB
• d722658d8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Directors On January 16, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Day One Biopharmaceuticals, Inc. (the "Company"), the Board increased the size of the Board to ten directors and appointed each of Habib J. Dable and William Grossman as a Class III and Class II director, respectively, effective as of January 17, 2024 (the "Effective Date"). In connection with his appointment as a non-employee director of the Board, and in accordance with the Company's current compensation policy for non-employee directors (the "Compensation Policy"), the Board granted to each of Mr. Dable and Dr. Grossman a stock option to purchase shares of the Company's common stock with an aggregate value of $588,000, calculated in accordance with the Compensation Policy (the "Initial Grants"). The Initial Grants shall vest monthly over three years, beginning on the one-month anniversary of the Effective Date, subject, however, to each of Mr. Dable's and Dr. Grossman's respective continued service on the Board on each vesting date. Pursuant to the Compensation Policy, on the date of each annual meeting of the Company's stockholders, each non-employee director who is serving on the Board prior to, and will continue to serve on the Board following, such meeting is entitled to an annual stock option grant for shares of the Company's common stock with an aggregate value of $294,000 (the "Annual Grant"), calculated in accordance with the Compensation Policy. Each of Mr. Dable and Dr. Grossman will be eligible for Annual Grants, provided, that, he satisfies the requirements set forth in the Compensation Policy, including the service requirements. The Initial Grant and any Annual Grants awarded to each of Mr. Dable and Dr. Grossman will

01

Item 7.01 Regulation FD Disclosure. On January 17, 2024, the Company issued a press release announcing the appointments disclosed above. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 to this report, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated January 17, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: January 17, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR